CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice Report From the Laboratory Science Discussion Group
暂无分享,去创建一个
N. Rifai | J. Catravas | R. Alexander | G. Cooper | R. Tracy | E. Stein | K. Taubert | G. Myers | T. Cole | B. Khan | W. Roberts | G. Warnick | L. Biasucci | M. M. Kimberly | P. Waymack
[1] A. Işık,et al. Predictive Value of C-reactive Protein in Patients with Unstable Angina Pectoris Undergoing Coronary Artery Stent Implantation , 2004, The Journal of international medical research.
[2] J. Kaski,et al. Pregnancy-Associated Plasma Protein A and Its Endogenous Inhibitor, the Proform of Eosinophil Major Basic Protein (proMBP), Are Related to Complex Stenosis Morphology in Patients With Stable Angina Pectoris , 2004, Circulation.
[3] S. Reis,et al. Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.
[4] C. Heeschen,et al. Prognostic value of placental growth factor in patients with acute chest pain. , 2004, JAMA.
[5] W. Markiewicz,et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. , 2003, The American journal of medicine.
[6] J. Tijssen,et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. , 2003, The American journal of medicine.
[7] J. Tijssen,et al. The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. , 2003, The American journal of medicine.
[8] P. Porela,et al. Circulating Pregnancy-Associated Plasma Protein A Predicts Outcome in Patients With Acute Coronary Syndrome but No Troponin I Elevation , 2003, Circulation.
[9] C. Heeschen,et al. Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.
[10] E. Edelman,et al. Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.
[11] Nader Rifai,et al. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. , 2003, Clinical chemistry.
[12] R. Califf,et al. N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.
[13] B. Horne,et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? , 2003, Journal of the American College of Cardiology.
[14] F. Crea,et al. Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes , 2003, Circulation.
[15] Sidney C. Smith,et al. MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .
[16] D. Mannino,et al. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. , 2003, Clinical chemistry.
[17] N. Rifai,et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. , 2003, Clinical chemistry.
[18] M. Woodward,et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. , 2003, Clinical chemistry.
[19] R. Califf,et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. , 2003, Journal of the American College of Cardiology.
[20] Robert J Glynn,et al. Alcohol Consumption and Plasma Concentration of C-Reactive Protein , 2003, Circulation.
[21] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[22] A. M. Johnson,et al. Commutability of the CRM 470 C-Reactive Protein Value in the Dade Behring N High Sensitivity CRP Assay , 2003, Clinical chemistry and laboratory medicine.
[23] Subrata Ghosh,et al. Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.
[24] A. Tedgui,et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes , 2002, Heart.
[25] Hyon K. Choi,et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. , 2002, The American journal of medicine.
[26] Deepak L. Bhatt,et al. Need to test the arterial inflammation hypothesis. , 2002, Circulation.
[27] Paul M. Ridker,et al. Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death , 2002, Circulation.
[28] Nader Rifai,et al. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.
[29] S. Marsch,et al. Inflammation and Long-Term Mortality After Non-ST Elevation Acute Coronary Syndrome Treated With a Very Early Invasive Strategy in 1042 Consecutive Patients , 2002, Circulation.
[30] B. Horne,et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. , 2002, Journal of the American College of Cardiology.
[31] A. Maseri,et al. Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease: Predictive Role of C-Reactive Protein , 2002, Circulation.
[32] A. Abbate,et al. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. , 2002, The American journal of cardiology.
[33] U. Prabhakar,et al. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. , 2002, Journal of immunological methods.
[34] M. V. van Dieijen-Visser,et al. High-sensitivity C-reactive protein methods examined. , 2002, Clinical chemistry.
[35] P. Ridker,et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. , 2002, The American journal of cardiology.
[36] Cynthia A. Carnes,et al. C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.
[37] N. Rifai,et al. Performance characteristics of a point of care C-reactive protein assay. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[38] O. Wagner,et al. Evaluation of turbidimetric high-sensitivity C-reactive protein assays for cardiovascular risk estimation. , 2001, Clinical chemistry.
[39] A. Tedgui,et al. Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability , 2001, Circulation.
[40] Deepak L. Bhatt,et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.
[41] Deepak L. Bhatt,et al. Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.
[42] J. Kooner,et al. C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites , 2001, Circulation.
[43] K. Kayaba,et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. , 2001, American journal of epidemiology.
[44] R. Pizarro,et al. C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. , 2001, The American journal of cardiology.
[45] P. Crean,et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules , 2001, Heart.
[46] S. Grundy,et al. Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.
[47] P. Mills,et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. , 2001, Journal of the American College of Cardiology.
[48] V. Rizzello,et al. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.
[49] C. Kluft,et al. Determination of the habitual low blood level of C-reactive protein in individuals. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.
[50] S. Fichtlscherer,et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. , 2001, Journal of the American College of Cardiology.
[51] N Rifai,et al. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. , 2001, Clinical chemistry.
[52] P. Ridker,et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. , 2001, Clinical chemistry.
[53] N Rifai,et al. High Sensitivity Immunoassays for C-Reactive Protein: Promises and Pitfalls , 2001, Clinical chemistry and laboratory medicine.
[54] N Rifai,et al. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. , 2001, Clinical chemistry.
[55] N Rifai,et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. , 2001, Clinical chemistry.
[56] S. Anker,et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.
[57] G. Biondi-Zoccai,et al. Prognostic value of C-reactive protein in unstable angina. , 2000, Circulation.
[58] B. Horne,et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. , 2000, Journal of the American College of Cardiology.
[59] S. Humphries,et al. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. , 2000, Cytokine.
[60] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[61] M H Wener,et al. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. , 2000, The Journal of rheumatology.
[62] P. Gaffney,et al. A Collaborative Study to Establish the 2nd International Standard for Fibrinogen, Plasma , 2000, Thrombosis and Haemostasis.
[63] L. Wallentin,et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial , 2000, The Lancet.
[64] M. Pfeffer,et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.
[65] C. Heeschen,et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. , 2000, Journal of the American College of Cardiology.
[66] N. Rifai,et al. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. , 2000, Clinical chemistry.
[67] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[68] K. Huber,et al. The association between C‐reactive protein on admission and mortality in patients with acute myocardial infarction , 2000, Journal of internal medicine.
[69] E. Antman,et al. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. , 2000, Journal of the American College of Cardiology.
[70] M. Pepys,et al. C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.
[71] P. Pasqualetti,et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. , 1999, Journal of the American College of Cardiology.
[72] M. Leon,et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. , 1999, The American journal of cardiology.
[73] A. Maseri,et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. , 1999, The American journal of cardiology.
[74] C. Held,et al. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. , 1999, European heart journal.
[75] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[76] E. Carluccio,et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. , 1999, The American journal of cardiology.
[77] A. Rebuzzi,et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.
[78] A. Zwinderman,et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. , 1999, European heart journal.
[79] A. Rebuzzi,et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.
[80] A. Döring,et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.
[81] J. Sipe,et al. Analytical Evaluation of Particle-Enhanced Immunonephelometric Assays for C-Reactive Protein, Serum Amyloid a and Mannose-Binding Protein in Human Serum , 1998, Annals of clinical biochemistry.
[82] E. Holler,et al. Validation of an Automated Enzyme Immunoassay for Interleukin-6 for Routine Clinical Use , 1998, Clinical chemistry and laboratory medicine.
[83] E. Vicaut,et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. , 1998, The American journal of cardiology.
[84] A. Rebuzzi,et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. , 1998, The American journal of cardiology.
[85] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[86] M. Pepys,et al. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. , 1998, Clinical chemistry.
[87] M. Hino,et al. Problems with assays based on fibrin clot formation principle: analysis of multilaboratory data. , 1998, Osaka city medical journal.
[88] M. Pepys,et al. The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. , 1998, Journal of immunological methods.
[89] R. De Cristofaro,et al. Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[90] E. Antman,et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.
[91] Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.
[92] A. Siegbahn,et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 1997, Circulation.
[93] D. Ardissino,et al. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. , 1997, The American journal of cardiology.
[94] S. Ogawa,et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.
[95] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[96] R. Thorpe,et al. Implications for the assay and biological activity of interleukin-8: results of a WHO international collaborative study. , 1997, Journal of immunological methods.
[97] R. Tracy,et al. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.
[98] G. Ciliberto,et al. Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.
[99] A. Pasternack,et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. , 1996, European heart journal.
[100] J. Cavaillon,et al. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. , 1995, Journal of immunological methods.
[101] G. Assmann,et al. Fibrinogen and Cardiovascular Risk , 1995, Journal of cardiovascular risk.
[102] S. Thompson,et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.
[103] I. Mackie,et al. Inaccuracy of the 'derived' fibrinogen measurement. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[104] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[105] W. G. Wood,et al. The Limitations and Usefulness of C-Reactive Protein and Elastase-α1-Proteinase Inhibitor Complexes as Analytes in the Diagnosis and Follow-up of Sepsis in Newborns and Adults , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[106] J. Bienvenu,et al. Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-alpha. A WHO study. , 1993, European cytokine network.
[107] C. Fraser,et al. Biological Variation of Acute Phase Proteins , 1993, Annals of clinical biochemistry.
[108] S. Poole,et al. The international standard for interleukin-6. Evaluation in an international collaborative study. , 1993, Journal of immunological methods.
[109] A. Dobson,et al. Effect of processing time and storage on fibrinogen content of EDTA plasma assayed by radial immunodiffusion. , 1992, Clinical chemistry.
[110] S. Ehrmeyer,et al. The relationship of intralaboratory bias and imprecision on laboratories' ability to meet medical usefulness limits. , 1988, American journal of clinical pathology.
[111] DifcoTM HycheckTM,et al. The package insert. , 1969, JAMA.
[112] Mark Woodward,et al. Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States : Implication for Clinical Interpretation , 2022 .